To nullify the modifications made by the Food and Drug Administration in January 2023 to the risk evaluation and mitigation strategy for the abortion pill mifepristone, and for other purposes.
U.S. Congress · HR679 ·
Introduced
In Committee
Reported
Floor
Passed Chamber
Enacted
What the bill says
Introduced 2025-01-23. Latest action: Referred to the House Committee on Energy and Commerce.
Sponsors
- Diana Harshbarger (primary)
- Brian Babin
- Mike Bost
- Andy Biggs
- James R. Baird
- Sheri Biggs
- Randy Feenstra
- Michael Guest
- Andy Harris
- Clay Higgins
- Kevin Hern
- John R. Moolenaar
- Mary E. Miller
- Mark B. Messmer
- Gary J. Palmer
- Keith Self
- Daniel Webster
- Randy K. Weber, Sr.
- Rudy Yakym III
Text versions
- Introduced in House — 2025-01-23 — XML
What analysts say
No nonpartisan analysis on file for this measure yet.
What politicians say
No linked claims or utterances yet — no one on record has cited this measure to justify a public argument.
Action History
| Date | Action |
|---|---|
| 2025-01-23 | Introduced in House |
| 2025-01-23 | Referred to the House Committee on Energy and Commerce. |
Lobbying on this bill
Showing 4 of 4 bill mentions.
Honesty note: each filer below disclosed lobbying on this bill — that much the filing tells us. But the dollar figure is their total lobbying spend for the whole quarter across all their issues, not the amount spent on this bill, and the filing never says whether they supported or opposed it.
| Registrant (lobbying firm) | Client | Period | Reported quarterly amount | Extraction |
|---|---|---|---|---|
| SUSAN B ANTHONY LIST | SUSAN B ANTHONY LIST | Q1 2026 | $380,000 | |
| SUSAN B ANTHONY LIST | SUSAN B ANTHONY LIST | Q1 2026 | $380,000 | |
| SUSAN B ANTHONY LIST | SUSAN B ANTHONY LIST | Q1 2026 | $380,000 | |
| SUSAN B ANTHONY LIST | SUSAN B ANTHONY LIST | Q1 2026 | $380,000 |
Source: Senate LDA filings.